We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Disease control and reduced glucocorticoid doses ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

Emerging treatments for classic congenital adrenal hyperplasia (CAH) may make it easier to manage the condition, which occurs when you dont have enough of the enzyme you need to make the hormones ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) said that the U.S. Food and Drug Administration has approved CRENESSITY (crinecerfont) capsules and oral solution as an adjunctive treatment to ...

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH) due to ...

Classic congenital adrenal hyperplasia (CAH) is a condition that is passed down in families. It is a serious condition that can be deadly if not treated. One of the treatments for classic CAH is ...

People with classic congenital adrenal hyperplasia (CAH) may suffer from impaired bone health, largely due to standard treatments. Most often caused by a genetic mutation in the 21-hydroxylase enzyme, ...

Steroids like glucocorticoids may be the cornerstone of your treatment when you have congenital adrenal hyperplasia (CAH). In classical CAH, steroids replace the cortisol and aldosterone your body can ...

People with classic congenital adrenal hyperplasia (CAH) often experience fertility issues, but hormone-balancing treatment can help. This rare genetic disorder is most often caused by a ...

(RTTNews) - BridgeBio Pharma Inc. (BBIO) said that it will no longer be pursuing development of BBP-631 for Congenital Adrenal Hyperplasia. The company is actively seeking partnership opportunities to ...

Phyllis Speiser is emeritus professor of pediatrics at Zucker School of Medicine at Hofstra-Northwell and associate investigator at The Feinstein Institute for Medical Research of Northwell Health.